Financial Data and Key Metrics Changes - Consolidated sales decreased by 2.2% to $80.3 million, with a $700,000 decrease from retail stores and a $1.1 million decrease from external wholesale customers, primarily due to winter weather impacts [14][3] - Gross margin decreased by 80 basis points to 56.2%, driven by lower margins in both retail and wholesale businesses [14][15] - Operating income was $1.2 million, or 1.4% of sales, compared to $2.5 million, or 3% of sales in the prior period [15] - Diluted earnings per share were $0.13, down from $0.21 [15] Business Line Data and Key Metrics Changes - Retail net sales were $52.5 million, a decrease of 1.4%, primarily due to winter weather impacts [17] - Written sales decreased by 0.2%, while gross margin for retail was 51.5%, down 170 basis points due to delayed price increases related to tariffs [17][4] - Wholesale net sales were $53 million, essentially flat year-over-year, with a 0.6% increase in shipments to the retail core network [16] Market Data and Key Metrics Changes - The company experienced a significant decline in retail written sales during a two-week period in January due to severe weather, impacting both retail and wholesale operations [3][48] - The overall traffic was down in the first quarter, but conversions increased by 130%, resulting in a 28% increase in orders [10] Company Strategy and Development Direction - The company is focusing on five key initiatives to grow the business, including generating comparable store growth, opening new retail locations, increasing e-commerce sales, enhancing Bassett Design Centers, and building the interior design channel [6][12] - The company plans to open corporate stores in Cincinnati and Orlando and relocate a store on Long Island, with meticulous research on sales potential before committing to new locations [9] - Investments are being made to enhance the e-commerce platform and integrate an omni-channel experience, targeting younger, higher-income demographics [10] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing challenges in the macro environment, including weak residential housing activity and higher employee costs, which are headwinds for top-line growth [5] - The company is optimistic about improved retail margins in the upcoming quarters due to the implementation of price increases [22] - Management expressed that while there has not been a significant decline in business trends since the start of the conflict in Ukraine, there has also not been an uptick [31] Other Important Information - The company plans to spend between $8 million and $12 million on capital expenditures for 2026, significantly higher than the previous year's $4.5 million [19] - The company remains committed to delivering shareholder returns through dividends and opportunistic share buybacks, with a quarterly dividend of $0.20 approved [19] Q&A Session Summary Question: Impact of delayed price increases on retail margins - Management acknowledged the impact of delayed price increases and indicated that margins should improve in the second quarter [22][23] Question: Potential additional pricing actions due to fuel price spikes - Management confirmed that surcharges related to freight and petroleum derivative products will need to be passed along to customers [25] Question: Trends observed since the start of the conflict in Ukraine - Management reported no significant changes in business trends, maintaining a steady performance [31] Question: Accessibility to materials and potential price increases - Management indicated no noticeable issues with material accessibility and container prices have not spiked [37] Question: Outlook for retail margins and new store openings - Management expects some losses on the retail side until new stores start producing sales, but anticipates better margins moving forward [39][40] Question: Potential for tariff refunds and impact on the tariff landscape - Management stated that there is uncertainty regarding tariff refunds and the impact of recent Supreme Court decisions [41] Question: Weather impact on sales - Management expressed hope that lost sales due to weather would be deferred rather than permanently lost, but noted significant impacts on retail written sales [44][45] Question: E-commerce sales representation and future reporting - Management indicated that while e-commerce sales are growing, they have not broken out these figures separately in the past [49]

Financial Data and Key Metrics Changes - Consolidated sales decreased by 2.2% to $83 million, a decline of $1.8 million compared to the previous year [14] - Gross margin decreased by 80 basis points to 56.2%, primarily due to lower margins in both retail and wholesale businesses [14] - Operating income was $1.2 million, or 1.4% of sales, down from $2.5 million, or 3% of sales in the prior period [15] - Diluted earnings per share were $0.13, compared to $0.21 in the previous year [15] Business Line Data and Key Metrics Changes - Retail net sales were $52.5 million, a decrease of $800,000 or 1.4%, primarily due to winter weather impacts [17] - Wholesale net sales were $53 million, essentially flat compared to last year, with a 0.6% increase in shipments to the retail core network [16] - Written sales were flat for the first quarter, but there was a double-digit increase in written orders for the back half of February [4] Market Data and Key Metrics Changes - The company experienced significant disruptions in retail and wholesale sales due to severe weather, with over 50% of retail locations closed during critical weekends [4] - The macro environment remains challenging with weak residential housing activity and higher employee costs impacting sales [5] Company Strategy and Development Direction - The company is focusing on five key initiatives to drive growth: generating comparable store growth, opening additional retail locations, increasing e-commerce sales, enhancing Bassett Design Centers, and building the interior design channel [13] - The company plans to open corporate stores in Cincinnati and Orlando and relocate a store on Long Island [9] - Investments are being made to improve e-commerce capabilities and integrate an omni-channel experience [10] Management's Comments on Operating Environment and Future Outlook - Management noted that the pace of business slowed abruptly in mid-January, impacting sales and margins [3] - There is cautious optimism regarding improved retail margins due to recent price adjustments [22] - The company is addressing higher SG&A expenses and is implementing initiatives projected to save between $1.5 million and $2 million annually [5] Other Important Information - The company maintains a solid liquidity position with $51 million in cash and short-term investments [18] - Total capital expenditures for 2026 are expected to be between $8 million and $12 million, significantly higher than the previous year's $4.5 million [19] - The company continues to pay dividends and repurchase shares opportunistically, with a $0.20 dividend approved for payment on May 29 [19] Q&A Session Summary Question: Impact of delayed price increases on retail margins - Management acknowledged the impact of delayed price increases and indicated that margins should improve in the second quarter [22][23] Question: Potential additional pricing actions due to fuel price spikes - Management confirmed that surcharges related to fuel prices are already being implemented and will need to be passed along to customers [24][25] Question: Trends observed since the start of the conflict in Ukraine - Management reported no significant changes in trends, with sales remaining stable but not showing an uptick [32] Question: Accessibility to materials and potential price increases - Management indicated no noticeable issues with accessibility to materials and did not foresee immediate price increases due to geopolitical tensions [38] Question: Outlook for retail margins and new store openings - Management expects some losses in retail margins until new stores begin generating sales, but anticipates better margins moving forward [40][41] Question: Potential for tariff refunds and impact of Supreme Court decision - Management stated that there is uncertainty regarding tariff refunds and the impact of recent legal decisions [42] Question: Weather impact on sales - Management expressed hope that lost sales due to weather would be deferred rather than permanently lost, but acknowledged the significant impact on sales [45][46] Question: E-commerce sales representation and future reporting - Management noted that while e-commerce sales are growing, they have not broken out these figures separately in the past [50]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in lead and consult volumes, which have continued into 2026, contributing to improved revenue trends [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focused on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with same-store sales improving from down 22% at the start of 2025 to positive in February 2026 [5] - The company expects revenue in 2026 to range from $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management expressed confidence in the full-year outlook, citing improved trends and a focus on execution [22] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - A reconciliation matter related to intercompany transactions was identified, leading to immaterial changes in prior year balances, but had no impact on revenue or cash [13] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management acknowledged improved trends and emphasized the need for consistent results to meet guidance [22] Question: Can you provide insights on body sculpting trends outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1s expected to drive future demand [23] Question: What feedback have you received from customers and surgeons regarding excisional procedures? - Management reported positive early results from patients and comfort among surgeons, with plans to ramp up procedures throughout the year [27] Question: How should capital allocation be viewed going forward regarding debt pay down versus investments? - Management indicated that the priority remains on maintaining a healthy balance sheet while also investing back into the business for growth initiatives [29]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in lead and consult volumes, contributing to better revenue trends moving into 2026 [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focusing on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with same-store sales improving from down 22% at the start of 2025 to positive in February 2026 [5] - The company expects revenue in 2026 to range from $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management acknowledged the need to monitor the helium plasma supply situation due to geopolitical issues affecting skin tightening procedures [18] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - Cash flow from operations for the year was $3.1 million, down from $11.4 million in fiscal 2024 [17] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management indicated that trends have improved significantly, and they are focused on execution to ensure they meet their numbers [22] Question: Can the company isolate market trends for the core business outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1 being the next wave of change [23] Question: What feedback has the company received regarding excisional procedures from the pilot phase? - Management reported excellent results from patients and comfort from surgeons, with plans to ramp up procedures as the year progresses [27] Question: How should capital allocation be viewed going forward regarding debt pay down versus business investment? - Management emphasized the priority of maintaining a healthy balance sheet while also investing back into the business for growth initiatives [29]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in same-store sales, which improved from down 22% at the start of 2025 to positive growth in February 2026 [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focusing on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with a focus on stabilizing the core business and improving operational performance [5] - For 2026, the company expects revenue in the range of $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management expressed confidence in the full-year outlook, citing improved trends and a focus on execution [21] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - A reconciliation matter related to intercompany transactions was identified, leading to immaterial changes in prior year balances, but had no impact on revenue or cash [13] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management acknowledged improved trends and emphasized the need for consistent results to meet guidance [21] Question: Can the company isolate market trends for the core business outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1s expected to drive future demand [22] Question: Feedback on excisional procedures pilot and plans for broader rollout? - Management reported excellent results from the pilot, with positive feedback from patients and surgeons, and plans to ramp up procedures throughout the year [25] Question: Thoughts on capital allocation and debt pay down strategy? - Management indicated that the priority remains on maintaining a healthy balance sheet, with plans to refinance debt while investing back into the business [28]

Financial Data and Key Metrics Changes - The company reported net sales of $1.1 billion, which was $49 million or 5% above the prior year, driven by growth in Acuity Intelligent Spaces (AIS) [15] - Adjusted operating profit was $176 million, an increase of $13 million or 8% from last year, with an adjusted operating profit margin of 16.7%, up 50 basis points from the prior year [15] - Adjusted diluted earnings per share increased to $4.14, reflecting an increase of $0.41 or 11% compared to the prior year [16] Business Line Data and Key Metrics Changes - Acuity Brands Lighting (ABL) sales were $817 million, a decrease of $23 million or 3% versus the prior year, primarily due to declines in the direct sales channel [16] - ABL delivered a gross profit margin of 45.7%, an increase of 70 basis points compared to the prior year, driven by strategic pricing and productivity improvements [16] - AIS sales for the second quarter were $248 million, an increase of $77 million, driven by strong growth in Distech and QSC [17] Market Data and Key Metrics Changes - The company expects full-year ABL sales performance to be flat to down low single digits year-over-year, reflecting current market dynamics [12] - The impact of data centers is creating a crowding out effect on labor and project releases, leading to slower project timelines [28] Company Strategy and Development Direction - The company is focused on product vitality, elevating service levels, and using technology to improve operations and drive productivity [5] - The growth algorithm aims to ensure the company outgrows the lighting market by entering new verticals and taking market share [6] - The company is confident in the long-term performance of both the lighting and spaces businesses, with a focus on growth and margin expansion [13] Management's Comments on Operating Environment and Future Outlook - Management noted that the market is seeking consistency around policy and tariffs, which is impacting project timelines [27] - The company is managing gross profit margins through strategic pricing and productivity improvements, positioning itself well for future opportunities [12] - Management expressed confidence in the ability to adapt to changes in the market, including potential tariff impacts [32] Other Important Information - The company generated $230 million of cash flow from operations in the first half of fiscal 2026, which was $38 million higher than the same period in fiscal 2025 [18] - The company repaid $100 million of its term loan during the quarter, bringing the total repaid this year to $200 million [18] - The quarterly dividend was increased by 18% to $0.20 per share, and $106 million was allocated to repurchase shares [19] Q&A Session Summary Question: Demand trends in ABL - Management highlighted that the market is looking for consistency and that project releases are slower than historically observed, with no indication of losing market share [28][29] Question: Impact of tariffs - Management stated that they have a dynamic supply chain and have managed through tariffs effectively, with most products being unaffected by potential new tariffs [32] Question: ABL gross margin drivers - Management attributed the increase in ABL gross margins to productivity improvements and strategic pricing, with confidence in continuing this trend [36][39] Question: Cost pressures and price increases - Management acknowledged some cost pressures due to data centers impacting labor availability but indicated they would manage through it as they have in the past [49][50] Question: AIS revenue outlook - Management confirmed no change to the AIS growth outlook, expecting low- to mid-teens growth for the year [89]

Financial Data and Key Metrics Changes - Cheche Group achieved adjusted net income of RMB 11.6 million or $1.7 million for the full year 2025, a significant improvement from an adjusted net loss of RMB 24.8 million in the prior year, marking a swing of over RMB 35 million [5] - Total written premiums increased by 11% year-over-year to RMB 27 billion or $3.9 billion for the full year 2025 [14] - Net revenues for the full year 2025 were RMB 3.0 billion or $430.4 million, a decrease of 13.3% year-over-year, primarily due to the higher proportion of NEV premiums [16] Business Line Data and Key Metrics Changes - NEV premiums represented 24.1% of total written premiums in the second half of 2025, up from 17.2% in the prior year period, and 23.4% for the full year 2025, up from 13.6% in the prior year [15] - The total number of policies issued grew from 17.3 million to 20.3 million for the full year 2025 [14] Market Data and Key Metrics Changes - Cheche's partnerships with 16 NEV manufacturers generated 1.2 million embedded policies and RMB 3.7 billion in written premiums in the second half of 2025, representing year-over-year growth of 61.8% and 63.9% respectively [15] - Chinese automakers are exporting over 8 million vehicles annually, creating a demand for intelligent data-driven insurance and financial services [12] Company Strategy and Development Direction - The company is transitioning from a transactional insurance platform to an AI-powered intelligent insurance ecosystem, focusing on enhancing operational capabilities through AI [4][10] - Cheche aims to deepen existing partnerships with NEV manufacturers and expand into international markets, leveraging its digital insurance and financial technology capabilities [11][12] Management's Comments on Operating Environment and Future Outlook - Management highlighted the resilience of the business model despite fee rate compression and expressed confidence in the trajectory of the business moving into 2026 [4][13] - The company anticipates a significant increase in NEV premiums for 2026, projecting growth between 66.7% and 90.5% year-over-year [29] Other Important Information - The company reported RMB 160.8 million or $24.4 million in cash equivalents as of December 31, 2025 [22] - Cheche expects adjusted net income to multiply several folds compared to the full year of 2025 [23] Q&A Session Summary Question: What will drive strong adoption of NEV premiums? - Management emphasized the integration of AI across workflows to enhance efficiency and the use of AI tools to extend capabilities across the insurance value chain [30][31] Question: Can you explain your fintech solutions for international expansion? - Management described strategic partnerships with automotive brands to support Chinese automakers in their overseas expansion, leveraging digital insurance capabilities [32][33] Question: How is AI being leveraged to reduce operating costs? - Management acknowledged the internal use of AI to support operations but did not provide specific details in the response [45]

Financial Data and Key Metrics Changes - Revenue increased by 8.9% to $78.4 million, driven by growth in both MedTech and Med Device segments [13] - Adjusted EBITDA improved to $1.8 million from $1.3 million year-over-year, attributed to MedTech revenue growth and operational efficiency [18] - Gross margin for Q3 FY 2026 was 52.9%, a decrease of 110 basis points from the previous year, primarily due to tariffs and inflation [16] Business Line Data and Key Metrics Changes - MedTech revenue reached $37.3 million, a 19% increase, comprising 48% of total revenue compared to 44% a year ago [13] - Auryon platform generated $16.3 million in revenue, growing 17.9% year-over-year, marking 19 consecutive quarters of double-digit growth [13][14] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, increased by 17.9% to $11.5 million, with AlphaVac revenue growing 47.4% year-over-year [14] Market Data and Key Metrics Changes - The Med Device segment saw a modest increase of 1.1% year-over-year, with a year-to-date growth of 3% [15] - NanoKnife revenue increased by 21% to $7.6 million, driven by strong demand in prostate care and capital sales [15] Company Strategy and Development Direction - The company is focused on driving profitable growth in high-margin MedTech markets, with a strategic shift towards hospital settings [5][41] - Continued investment in R&D is planned, targeting approximately 10% of sales to support long-term growth [17] - The company is raising its full-year guidance for net sales and adjusted EBITDA for the third consecutive quarter, reflecting confidence in its growth strategy [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business despite macroeconomic challenges, including tariffs and inflation [5][19] - The company anticipates continued growth in the AlphaVac product line and expects to maintain strong performance in the MedTech segment [30][38] Other Important Information - The company plans to increase inventory levels in anticipation of temporary sterilization shutdowns, which may slightly impact cash flow [23][50] - The leadership transition process is underway, with a search committee formed to find a successor for the current CEO [24] Q&A Session Summary Question: AlphaVac sequential growth drivers and impact of PE guidelines - Management noted that growth is driven by new hospital approvals and physician comfort with the product, expecting continued sequential growth [29][30] Question: Guidance impact from higher energy costs and supplier costs - Management confirmed that guidance accounts for inflationary pressures and tariffs, with some ability to raise prices on superior products [32][33] Question: Future baseline for AlphaVac revenue - Management expects AlphaVac to continue growing sequentially, viewing current revenue as a strong driver for future growth [38] Question: Auryon volume versus price dynamics - Management highlighted the strategic shift towards hospital settings, which supports pricing and volume growth, and expects Auryon to continue growing [40][41] Question: Supply chain exposure to China and sterilization shutdowns - Management indicated minimal risk from China sourcing and noted that sterilization shutdowns are not frequent, with plans in place to mitigate any disruptions [48][50]

Financial Data and Key Metrics Changes - Cheche Group achieved adjusted net income of RMB 11.6 million or $1.7 million for the full year 2025, a significant improvement from an adjusted net loss of RMB 24.8 million in the prior year, marking a swing of over RMB 35 million [5][21] - Total written premiums increased by 11% year-over-year to RMB 27 billion or $3.9 billion for the full year 2025, with a total of 20.3 million policies issued, up from 17.3 million in the prior year [14][15] - The company reported a net revenue of RMB 3.0 billion or $430.4 million for the full year 2025, a decrease of 13.3% year-over-year, attributed to a higher proportion of NEV premiums [16] Business Line Data and Key Metrics Changes - NEV premiums represented 24.1% of total written premiums in the second half of 2025, up from 17.2% in the prior year period, indicating a shift towards higher margin business [15][16] - The number of NEV-embedded policies reached 2.0 million for the full year 2025, with corresponding premiums growing 91.0% to RMB 6.3 billion [15] Market Data and Key Metrics Changes - The company has established partnerships with 16 NEV manufacturers, generating significant growth in embedded policies and premiums [15] - Cheche Group is expanding its international presence, particularly in Asia and Latin America, leveraging its digital insurance and financial technology capabilities [12][33] Company Strategy and Development Direction - The company is transitioning from a transactional insurance platform to an AI-powered intelligent insurance ecosystem, focusing on enhancing operational capabilities through AI [4][6] - Cheche Group aims to deepen relationships with existing partners and expand its offerings within the NEV market, moving towards dynamic risk management [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, anticipating significant growth in NEV premiums and adjusted net income for 2026 [22] - The company is focused on cost management and operational efficiency, with total operating expenses decreasing by 19.6% for the full year 2025 [19] Other Important Information - The company reported RMB 160.8 million or $24.4 million in cash equivalents as of December 31, 2025, indicating a solid financial position [22] - Cheche Group plans to announce advancements in AI-driven auto pricing capabilities, which are expected to expand its addressable market [11] Q&A Session Summary Question: What will drive strong adoption of NEV premiums in 2026? - Management highlighted the integration of AI across workflows and the use of driving behavior data to enhance pricing, risk management, and fraud detection [30][32] Question: Can you explain your fintech solutions for international expansion? - The company has formed strategic partnerships with automotive brands and is leveraging its digital insurance capabilities to support Chinese automakers in their global expansion [33]

Financial Data and Key Metrics Changes - Revenue increased by 8.9% to $78.4 million, driven by growth in both MedTech and Med Device segments [13] - Adjusted EBITDA improved to $1.8 million from $1.3 million year-over-year, attributed to MedTech revenue growth and operational efficiency [18] - Gross margin for Q3 FY 2026 was 52.9%, a decrease of 110 basis points from the previous year, primarily due to tariffs and inflation [16] Business Line Data and Key Metrics Changes - MedTech revenue reached $37.3 million, a 19% increase year-over-year, comprising 48% of total revenue [13] - Auryon platform generated $16.3 million in revenue, growing 17.9% year-over-year, marking 19 consecutive quarters of double-digit growth [13] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, increased by 17.9% to $11.5 million, with AlphaVac revenue growing 47.4% year-over-year [14] Market Data and Key Metrics Changes - The Med Device segment saw a modest increase of 1.1% year-over-year, with a year-to-date growth of 3% [15] - NanoKnife revenue increased by 21% to $7.6 million, driven by strong demand in prostate care [15] Company Strategy and Development Direction - The company is focused on driving profitable growth in high-margin MedTech markets, with a strategic shift towards hospital settings [5][41] - Continued investment in R&D is planned, targeting approximately 10% of sales to support long-term growth [17] - The company is raising full-year guidance for net sales and adjusted EBITDA for the third consecutive quarter, reflecting confidence in growth strategies [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business despite macroeconomic uncertainties and challenges such as tariffs and inflation [5] - The company anticipates continued growth in the mechanical thrombectomy market and expects to maintain strong performance in the MedTech segment [9][38] Other Important Information - The company plans to increase inventory levels in anticipation of temporary sterilization shutdowns, which may slightly impact cash flow [23] - The leadership transition process is underway, with a search committee formed to find a successor for the CEO [24] Q&A Session Summary Question: What are the drivers behind AlphaVac's sequential growth? - Management noted that the growth is driven by increased hospital approvals and physician comfort with the product, expecting continued sequential growth [28][30] Question: Has the guidance accounted for higher energy costs and supplier costs? - Management confirmed that guidance includes expectations for inflationary costs and tariffs, with some ability to raise prices on superior products [32][33] Question: Should the $4.4 million AlphaVac revenue be viewed as a new baseline? - Management expects AlphaVac to continue growing sequentially, viewing the current revenue as a strong driver for future growth [38] Question: Can you provide insights on Auryon's performance in hospitals versus OBL? - Management highlighted a strategic shift towards hospital settings, which has positively impacted pricing and volume, while still maintaining growth in OBL [41][42] Question: What proportion of MedTech costs are exposed to China sourcing? - Management indicated that there is minimal risk from China sourcing, and inflationary impacts are being managed effectively [48]